HPV Vaccination Adherence in Working-Age Men: A Systematic Review and Meta-Analysis

Overview

Journal Vaccines (Basel)

Date 2023 Feb 28

PMID 36851321

Authors

Carlotta Amantea

Nazario Foschi

Filippo Gavi

Ivan Borrelli

Maria Francesca Rossi

Valerio Spuntarelli

Pierluigi Russo

Maria Rosaria Gualano

Paolo Emilio Santoro

Umberto Moscato

Affiliations

Soon will be listed here.

Abstract

Background: Human papillomavirus (HPV) infection is the most common sexually transmitted viral infection in the world. HPV vaccination adherence rates in men are generally lower than in women. The aim of this systematic review and meta-analysis was to assess adherence to HPV vaccination in young working-age males (18-30 years old).

Methods: A systematic review was performed using three databases: PubMed, Scopus, and Web of Science, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Results: After duplicate removal, the initial search resulted in 478 eligible papers. With the exclusion of 425 papers after screening the abstracts, full texts of 53 articles were reviewed. Subsequently, 45 were excluded. Among the eight studies included, four (50%) examined the vaccination adherence in young adults through data registered in nationwide insurance or private companies' databases, three (37.5%) in young adults in different settings through data collected from surveys and questionnaires, and one (12.5%) an HPV vaccination campaign in a family medicine residency practice.

Conclusion: Adherence to HPV vaccination in men of working age (18-30 years) does not appear to be adequate (pooled prevalence 11%). In order to achieve a higher level of compliance, it is important to place an emphasis on vaccination campaigns in schools as well as in the workplace, after consultation with and approval from local, regional, and federal public health agencies.

Citing Articles

Human Papillomavirus Infection in Partners of Women Attending Cervical Cancer Screening: A Pilot Study on Prevalence, Distribution, and Potential Use of Vaccines.

Sucato A, Serra N, Butta M, Gregorio L, Pistoia D, Capra G Vaccines (Basel). 2025; 13(2).

PMID: 40006719 PMC: 11861694. DOI: 10.3390/vaccines13020172.

Editorial: Tailoring treatment in invasive and non-invasive cervical pathology volume II.

Di Donato V, Golia DAuge T, Soderini A, Giannini A, Plotti F Front Surg. 2025; 11():1540134.

PMID: 39840259 PMC: 11747380. DOI: 10.3389/fsurg.2024.1540134.

Awareness and acceptance of human papillomavirus vaccine in the Middle East: A systematic review, meta-analysis, and meta-regression of 159 studies.

Gulle B, Kiran P, Celik S, Varol Z, Siyve N, Emecen A Epidemiol Infect. 2024; 152:e165.

PMID: 39655623 PMC: 11696605. DOI: 10.1017/S0950268824001596.

Longitudinal Screening for Oral High-Risk Non-HPV16 and Non-HPV18 Strains of Human Papillomavirus Reveals Increasing Prevalence among Adult and Pediatric Biorepository Samples: A Pilot Study.

Jacobs J, Chon E, Kingsley K Vaccines (Basel). 2024; 12(8).

PMID: 39204021 PMC: 11360083. DOI: 10.3390/vaccines12080895.

Coverage with the First Dose of Human Papillomavirus Vaccination among Females Aged 9-50 Years in Shenzhen, China: A Surveillance Based on Administrative Health Records in 2023.

Lin Z, Liang X, Su L, Peng W, Chen H, Fang Y Vaccines (Basel). 2024; 12(1).

PMID: 38250888 PMC: 10818281. DOI: 10.3390/vaccines12010075.

References

Saraiya M, Unger E, Thompson T, Lynch C, Hernandez B, Lyu C . US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015; 107(6):djv086. PMC: 4838063. DOI: 10.1093/jnci/djv086. View

Keim-Malpass J, McKim Mitchell E, Camacho F . HPV vaccination series completion and co-vaccination: Pairing vaccines may matter for adolescents. Vaccine. 2015; 33(43):5729-5732. PMC: 4612626. DOI: 10.1016/j.vaccine.2015.09.077. View

Reiter P, Brewer N, Gilkey M, Katz M, Paskett E, Smith J . Early adoption of the human papillomavirus vaccine among Hispanic adolescent males in the United States. Cancer. 2014; 120(20):3200-7. PMC: 4321105. DOI: 10.1002/cncr.28871. View

Edelstein Z, Carter J, Garg R, Winer R, Feng Q, Galloway D . Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis. 2011; 204(2):209-16. PMC: 3114468. DOI: 10.1093/infdis/jir242. View

Stanley M . Perspective: Vaccinate boys too. Nature. 2012; 488(7413):S10. DOI: 10.1038/488S10a. View

Wellnitz K, Sato Y, Bonthius D . Fatal Acute Hemorrhagic Leukoencephalitis Following Immunization Against Human Papillomavirus in a 14-Year-Old Boy. Child Neurol Open. 2021; 8:2329048X211016109. PMC: 8135193. DOI: 10.1177/2329048X211016109. View

Drolet M, Laprise J, Boily M, Franco E, Brisson M . Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2013; 134(9):2264-8. DOI: 10.1002/ijc.28541. View

Hirth J, Tan A, Wilkinson G, Berenson A . Completion of the human papillomavirus (HPV) vaccine series among males with private insurance between 2006 and 2009. Vaccine. 2013; 31(8):1138-40. PMC: 3563832. DOI: 10.1016/j.vaccine.2012.12.051. View

Clarke M, Coutinho F, Phelan-Emrick D, Wilbur M, Chou B, Joshu C . Predictors of Human Papillomavirus Vaccination in a Large Clinical Population of Males Aged 11 to 26 years in Maryland, 2012-2013. Cancer Epidemiol Biomarkers Prev. 2015; 25(2):351-8. PMC: 4767642. DOI: 10.1158/1055-9965.EPI-15-0983. View

10.

Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S . Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016; 4(9):e609-16. DOI: 10.1016/S2214-109X(16)30143-7. View

11.

Wiener R, Findley P, Shen C, Dwibedi N, Sambamoorthi U . Human papillomavirus (HPV) vaccine utilization among adults (18-29 years), BRFSS 2015. Vaccine. 2020; 38(33):5119-5122. PMC: 7367495. DOI: 10.1016/j.vaccine.2020.05.056. View

12.

Pierik R . On religious and secular exemptions: A case study of childhood vaccination waivers. Ethnicities. 2017; 17(2):220-241. PMC: 5428064. DOI: 10.1177/1468796817692629. View

13.

Serrano B, Alemany L, Tous S, Bruni L, Clifford G, Weiss T . Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2013; 7(1):38. PMC: 3554470. DOI: 10.1186/1750-9378-7-38. View

14.

Nasserie T, Bendavid E . Systematic identification and replication of factors associated with human papillomavirus vaccine initiation among adolescents in the United States using an environment-wide association study approach. Sex Transm Infect. 2021; 98(3):203-209. DOI: 10.1136/sextrans-2021-054976. View

15.

Yuen Loke A, Kwan M, Wong Y, Wong A . The Uptake of Human Papillomavirus Vaccination and Its Associated Factors Among Adolescents: A Systematic Review. J Prim Care Community Health. 2017; 8(4):349-362. PMC: 5932744. DOI: 10.1177/2150131917742299. View

16.

Hilton S, Hunt K, Bedford H, Petticrew M . School nurses' experiences of delivering the UK HPV vaccination programme in its first year. BMC Infect Dis. 2011; 11:226. PMC: 3176210. DOI: 10.1186/1471-2334-11-226. View

17.

Brisson M, Laprise J, Drolet M, Van de Velde N, Franco E, Kliewer E . Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine. 2013; 31(37):3863-71. DOI: 10.1016/j.vaccine.2013.06.064. View

18.

Sriram S, Ranganathan R . Why human papilloma virus vaccination coverage is low among adolescents in the US? A study of barriers for vaccination uptake. J Family Med Prim Care. 2019; 8(3):866-870. PMC: 6482788. DOI: 10.4103/jfmpc.jfmpc_107_19. View

19.

Newman P, Logie C, Lacombe-Duncan A, Baiden P, Tepjan S, Rubincam C . Parents' uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies. BMJ Open. 2018; 8(4):e019206. PMC: 5914890. DOI: 10.1136/bmjopen-2017-019206. View

20.

MacDonald R, Monga M, Fink H, Wilt T . Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med. 2008; 31(2):157-65. PMC: 2565485. DOI: 10.1080/10790268.2008.11760706. View